Inve India ▾

Novartis India share price & results

Novartis India Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Markets branded prescription medicines in Transplant, Established Medicines, Neuroscience & Oncology.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue104 ₹ crore+18.2% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin34.0 %+3.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit32.0 ₹ crore+14.3% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity12.11 %−1.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin13.19 %−8.0 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)5.40 %−6.8 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

10 targets tracked, none judged yet · 10 open · verdicts reflect calls analysed to Q1 FY27.

Novartis India Limited management guidance track record on Inve: 10 targets tracked across analysed earnings calls (0 achieved, 0 missed, 10 open).

TargetOriginal wordingSaidLatest callVerdict
Consolidated Revenueat least doubling up in next four to five years
Call transcript, Q1 FY27 · 11 Sept 2026		Q1 FY27Q1 FY27:From this base, I clearly see ourselves at least doubling up in next four to five years.
Call transcript, Q1 FY27 · 11 Sept 2026		New

Source: Inve Guidance Tracker for Novartis India Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

10 of Novartis India Limited's 10 targets are still open. See which are on track and which have gone quiet. The 1 above are the free sample; 9 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,847.8 +3.22% · +₹57.6

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +174.9% 1Y

₹1.0k₹1.5k₹2.0k₹2.5kOct 23Apr 26Sept 26Q1 FY27 — 11 Sept 2026

1Y: ₹672.25 on 25 Oct 2023 → ₹1,847.8. High ₹2,428.2 (10 Sept 2026), low ₹672.25 (25 Oct 2023).

Previous close
₹1,790.2
Market cap
₹4.5k Cr
52-week range
₹962 – ₹2,428.2
Price to earnings (TTM to Jun 2026)
46.44×
Return on equity (TTM to Jun 2026)
12.11%

Overview

Symbol
NSE:NOVARTIND
Exchange
NSE
Currency
INR

What Novartis India Limited does

Based on the company's own presentations, annual report and earnings calls.

Novartis India Limited is the Indian listed arm of Swiss pharmaceutical major Novartis, engaged in marketing and distributing branded prescription medicines to hospitals, doctors and retail pharmacies across India. Its portfolio spans four segments — Transplant, Established Medicines, Neurosciences and Oncology — comprising 24 brands. For its legacy Established Medicines brands (Voveran, Calcium range, Methergine), the company operates through a market-access partnership with Dr. Reddy's Laboratories, which commercialises these products leveraging its own distribution scale.

Segments

  • Transplant
  • Established Medicines
  • Neurosciences
  • Oncology
Reported operating segments (therapeutic areas)
4 (Transplant, Established Medicines, Neurosciences, Oncology)
Brands across therapeutic areas
24
Healthcare professionals reached (Established Medicines footprint)
113,000
Retail outlets reached (Established Medicines footprint)
80,000
Hospitals & medical colleges partnered (Transplant awareness/education)
400+
Transplant patients supported via Certican/Simulect (2024)
2,400+
Founded 1947Headquarters Mumbai, India Company website

How the price took the results

close before → close after

Q1 FY27
−1.5%
11 Sept

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Novartis India Limited

Free account: one company. Everything above stays public.

Write why you follow Novartis India Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Novartis India Limited

Guides on how to read this kind of business and the numbers that matter.